Risk factor
Very poor trading liquidity
Profitability factor
Very low or no dividends
About
Pharmosa Biopharm Inc., a biotechnology firm based in Taiwan, specializes in the development of pharmaceutical products. Its current pipeline includes two key candidates: L606 and L608. L606 is an investigational inhalation/device combination therapy designed to treat both pulmonary arterial hypertension and pulmonary hypertension linked to interstitial lung disease. Similarly, L608 is another inhalation-based therapy, paired with a device, aimed at addressing pulmonary vascular disease. The company, which was established in 2000, originally operated under the name Pharmosa Limited before adopting its current name, Pharmosa Biopharm Inc., in October 2016. Its main offices are located in Taipei City, Taiwan.
Company Valuation
Considering past and projected metrics, the stock is moderately 'expensive' compared to its peers.